| Year |
Citation |
Score |
| 2024 |
Roselle C, Horikawa I, Chen L, Kelly AR, Gonzales D, Da T, Wellhausen N, Rommel PC, Baker D, Suhoski M, Scholler J, O'Connor RS, Young RM, Harris CC, June CH. Enhancing chimeric antigen receptor T cell therapy by modulating the p53 signaling network with Δ133p53α. Proceedings of the National Academy of Sciences of the United States of America. 121: e2317735121. PMID 38408246 DOI: 10.1073/pnas.2317735121 |
0.321 |
|
| 2022 |
Akbari B, Hosseini Z, Shahabinejad P, Ghassemi S, Mirzaei HR, O'Connor RS. Metabolic and epigenetic orchestration of (CAR) T cell fate and function. Cancer Letters. 550: 215948. PMID 36209973 DOI: 10.1016/j.canlet.2022.215948 |
0.304 |
|
| 2022 |
Ghassemi S, Durgin JS, Nunez-Cruz S, Patel J, Leferovich J, Pinzone M, Shen F, Cummins KD, Plesa G, Cantu VA, Reddy S, Bushman FD, Gill SI, O'Doherty U, O'Connor RS, et al. Rapid manufacturing of non-activated potent CAR T cells. Nature Biomedical Engineering. 6: 118-128. PMID 35190680 DOI: 10.1038/s41551-021-00842-6 |
0.332 |
|
| 2021 |
Durgin JS, Thokala R, Johnson L, Song E, Leferovich J, Bhoj V, Ghassemi S, Milone M, Binder Z, O'Rourke DM, O'Connor RS. Enhancing CAR T Function with the Engineered Secretion of C. Perfringens Neuraminidase. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 34813961 DOI: 10.1016/j.ymthe.2021.11.014 |
0.351 |
|
| 2021 |
Garcia-Canaveras JC, Heo D, Trefely S, Leferovich J, Xu C, Philipson BI, Ghassemi S, Milone MC, Moon EK, Snyder NW, June CH, Rabinowitz JD, O'Connor RS. CAR T-Cells Depend on the Coupling of NADH Oxidation with ATP Production. Cells. 10. PMID 34571983 DOI: 10.3390/cells10092334 |
0.316 |
|
| 2021 |
Tu VY, Ayari A, O'Connor RS. Beyond the Lactate Paradox: How Lactate and Acidity Impact T Cell Therapies against Cancer. Antibodies (Basel, Switzerland). 10. PMID 34203136 DOI: 10.3390/antib10030025 |
0.325 |
|
| 2021 |
Tu VY, Ayari A, O'Connor RS. Beyond the Lactate Paradox: How Lactate and Acidity Impact T Cell Therapies against Cancer. Antibodies (Basel, Switzerland). 10. PMID 34203136 DOI: 10.3390/antib10030025 |
0.325 |
|
| 2020 |
Das RK, O'Connor RS, Grupp SA, Barrett DM. Lingering effects of chemotherapy on mature T cells impair proliferation. Blood Advances. 4: 4653-4664. PMID 33002133 DOI: 10.1182/bloodadvances.2020001797 |
0.322 |
|
| 2020 |
Ghassemi S, Martinez-Becerra FJ, Master AM, Richman SA, Heo D, Leferovich J, Tu Y, García-Cañaveras JC, Ayari A, Lu Y, Wang A, Rabinowitz JD, Milone MC, June CH, O'Connor RS. Enhancing Chimeric Antigen Receptor T Cell Anti-tumor Function through Advanced Media Design. Molecular Therapy. Methods & Clinical Development. 18: 595-606. PMID 32775494 DOI: 10.1016/J.Omtm.2020.07.008 |
0.34 |
|
| 2020 |
Philipson BI, O'Connor RS, May MJ, June CH, Albelda SM, Milone MC. 4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling. Science Signaling. 13. PMID 32234960 DOI: 10.1126/Scisignal.Aay8248 |
0.315 |
|
| 2020 |
O'Connor RS, Milone MC. Testing the Specificity of Compounds Designed to Inhibit CPT1A in T Cells. Methods in Molecular Biology (Clifton, N.J.). 2097: 83-90. PMID 31776920 DOI: 10.1007/978-1-0716-0203-4_5 |
0.406 |
|
| 2020 |
Klichinsky M, Ruella M, Shestova O, Best A, Blouch K, Lu XM, Kenderian SS, Kim MY, O'Connor R, Wallace S, Kozlowski M, Marchione DM, Shestov M, Garcia BA, June C, et al. Abstract PR07: Human chimeric antigen receptor (CAR) macrophages for cancer immunotherapy Cancer Immunology Research. 8. DOI: 10.1158/2326-6074.Tumimm18-Pr07 |
0.328 |
|
| 2020 |
Ghassemi S, Martinez-Becerra F, Master A, Richman S, Heo D, Leferovich J, Tu Y, Garcia-Canaveras J, Ayari A, Lu Y, Wang A, Rabinowitz J, Milone M, O'Connor R. Novel media formulations to enhance Chimeric Antigen Receptor (CAR) T-cell potency and anti-tumor cell function for adoptive immunotherapy Cytotherapy. 22: S133. DOI: 10.1016/J.Jcyt.2020.03.260 |
0.442 |
|
| 2020 |
Ghassemi S, O'Connor R, Nunez-Cruz S, Leferovich J, Patel J, Milone M. Chimeric Antigen Receptor (CAR) T cells on demand: developing potent CAR T cells in less than 24 hr for adoptive immunotherapy Cytotherapy. 22: S34-S35. DOI: 10.1016/J.Jcyt.2020.03.025 |
0.426 |
|
| 2019 |
Ghassemi S, O'Connor RS, Nunez-cruz S, Patel J, Leferovich J, Milone MC. Simple, 1-Day Manufacturing of Quiescent Chimeric Antigen Receptor T Cells for Adoptive Immunotherapy Blood. 134: 4436-4436. DOI: 10.1182/Blood-2019-131147 |
0.437 |
|
| 2019 |
Huarte E, O'Connor RS, Parker M, Huang T, Milone MC, Smith P. Prophylactic Itacitinib (INCB039110) for the Prevention of Cytokine Release Syndrome Induced By Chimeric Antigen Receptor T-Cells (CAR-T-cells) Therapy Blood. 134: 1934-1934. DOI: 10.1182/Blood-2019-128288 |
0.371 |
|
| 2019 |
Master A, O'Connor RS, Ghassemi S, Schneider DA, Karimi-Naser L. Abstract B029: A novel media supplementation strategy for improved T-cell culture and preservation of naivety Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-B029 |
0.427 |
|
| 2018 |
Ghassemi S, Nunez-Cruz S, O'Connor RS, Fraietta JA, Patel PR, Scholler J, Barrett DM, Lundh SM, Davis MM, Bedoya F, Leferovich J, Lacey SF, Levine BL, Grupp SA, June CH, et al. Reducing Ex Vivo Culture Improves the Anti-leukemic Activity of Chimeric Antigen Receptor (CAR)-T Cells. Cancer Immunology Research. PMID 30030295 DOI: 10.1158/2326-6066.Cir-17-0405 |
0.441 |
|
| 2018 |
Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, Boesteanu AC, Wang Y, O'Connor RS, Hwang WT, Pequignot E, Ambrose DE, Zhang C, Wilcox N, Bedoya F, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nature Medicine. PMID 29713085 DOI: 10.1038/S41591-018-0010-1 |
0.302 |
|
| 2018 |
O'Connor RS, Guo L, Ghassemi S, Snyder NW, Worth AJ, Weng L, Kam Y, Philipson B, Trefely S, Nunez-Cruz S, Blair IA, June CH, Milone MC. The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations. Scientific Reports. 8: 6289. PMID 29674640 DOI: 10.1038/S41598-018-24676-6 |
0.349 |
|
| 2017 |
Hippen KL, O'Connor RS, Lemire AM, Saha A, Hanse EA, Tennis NC, Merkel SC, Kelekar A, Riley JL, Levine BL, June CH, Kean LS, MacMillan ML, Miller JS, Wagner JE, et al. In vitro induction of human regulatory T-cells (iTregs) using conditions of low tryptophan plus kynurenines. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. PMID 28470889 DOI: 10.1182/Blood.V128.22.1229.1229 |
0.384 |
|
| 2017 |
Klichinsky M, Ruella M, Shestova O, Kenderian SS, Kim MY, O'Connor R, Scholler J, June C, Gill S. Abstract 4575: Chimeric antigen receptor macrophages (CARMA) for adoptive cellular immunotherapy of solid tumors Cancer Research. 77: 4575-4575. DOI: 10.1158/1538-7445.Am2017-4575 |
0.345 |
|
| 2016 |
Kawalekar OU, O'Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD, Patel PR, Guedan S, Scholler J, Keith B, Snyder N, Blair I, Milone MC, June CH. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. Immunity. 44: 380-390. PMID 26885860 DOI: 10.1016/J.Immuni.2016.01.021 |
0.32 |
|
| 2015 |
Saha A, O'Connor RS, Thangavelu G, Lovitch SB, Dandamudi DB, Wilson CB, Vincent BG, Aoyama K, Taylor PA, Panoskaltsis-Mortari A, Foncea R, Burrill JS, Guo L, Sacristan C, Furlan SN, et al. Loss of Programmed Death Ligand-1 Expression on Donor T Cells Lessens Acute Graft-Versus-Host Disease Lethality Blood. 126: 147-147. DOI: 10.1182/Blood.V126.23.147.147 |
0.351 |
|
| 2015 |
Kawalekar OU, O'Connor RS, Fraietta J, Guedan S, Scholler J, Milone MC, June CH. 516. Chimeric Antigen Receptors With Distinct Signaling Domains Can Reprogram T Cells Molecular Therapy. 23: S206-S207. DOI: 10.1016/S1525-0016(16)34125-9 |
0.412 |
|
| 2014 |
Kawalekar OU, O'Connor R, Guedan S, Fraietta J, Posey AD, Scholler J, Milone MC, June CH. Signaling Domain of Chimeric Antigen Receptors Can Reprogram T Cells Blood. 124: 551-551. DOI: 10.1182/Blood.V124.21.551.551 |
0.449 |
|
| 2012 |
O'Connor RS, Hao X, Shen K, Bashour K, Akimova T, Hancock WW, Kam LC, Milone MC. Substrate rigidity regulates human T cell activation and proliferation. Journal of Immunology (Baltimore, Md. : 1950). 189: 1330-9. PMID 22732590 DOI: 10.4049/jimmunol.1102757 |
0.314 |
|
| 2008 |
O'Connor RS, Steeds CM, Wiseman RW, Pavlath GK. Phosphocreatine as an energy source for actin cytoskeletal rearrangements during myoblast fusion. The Journal of Physiology. 586: 2841-53. PMID 18420707 DOI: 10.1113/Jphysiol.2008.151027 |
0.593 |
|
| 2007 |
O'Connor RS, Pavlath GK, McCarthy JJ, Esser KA. Last Word on Point:Counterpoint: Satellite cell addition is/is not obligatory for skeletal muscle hypertrophy. Journal of Applied Physiology (Bethesda, Md. : 1985). 103: 1107. PMID 17724310 DOI: 10.1152/Japplphysiol.00502.2007 |
0.656 |
|
| 2007 |
O'Connor RS, Pavlath GK. Point:Counterpoint: Satellite cell addition is/is not obligatory for skeletal muscle hypertrophy. Journal of Applied Physiology (Bethesda, Md. : 1985). 103: 1099-100. PMID 17289912 DOI: 10.1152/Japplphysiol.00101.2007 |
0.631 |
|
| 2007 |
O'Connor RS, Mills ST, Jones KA, Ho SN, Pavlath GK. A combinatorial role for NFAT5 in both myoblast migration and differentiation during skeletal muscle myogenesis. Journal of Cell Science. 120: 149-59. PMID 17164296 DOI: 10.1242/Jcs.03307 |
0.682 |
|
| 2006 |
Mitchell PO, Mills T, O'Connor RS, Kline ER, Graubert T, Dzierzak E, Pavlath GK. Corrigendum to "Sca-1 negatively regulates proliferation and differentiation of muscle cells" [Dev. Biol. 283 (2005) 240-252] (DOI:10.1016/j.ydbio.2005.04.016) Developmental Biology. 300: 785. DOI: 10.1016/J.Ydbio.2006.10.031 |
0.675 |
|
| 2005 |
Mitchell PO, Mills T, O'Connor RS, Kline ER, Graubert T, Dzierzak E, Pavlath GK. Sca-1 negatively regulates proliferation and differentiation of muscle cells. Developmental Biology. 283: 240-52. PMID 15901485 DOI: 10.1016/J.Ydbio.2005.04.016 |
0.668 |
|
| Show low-probability matches. |